Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited has announced the appointment of Cameron Bruce Price as a new director, effective from October 1, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, potentially impacting its strategic direction and stakeholder relations. Mr. Price holds no direct shares but has an indirect interest through his wife, who owns 3,296 ordinary shares.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative biotherapies and influenza vaccines. The company is a global leader in plasma-derived therapies and has a significant presence in the healthcare market.
Average Trading Volume: 1,147,974
Technical Sentiment Signal: Sell
Current Market Cap: A$96.55B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.